Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | S227928 |
Synonyms | |
Therapy Description |
S227928 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting CD74 linked to a MCL-1 inhibitor, which potentially induces cytotoxicity in CD74-expressing tumor cells (Blood (2024) 144 (Supplement 1): 604). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
S227928 | S-227928|S 227928 | CD74 Antibody 4 | S227928 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting CD74 linked to a MCL-1 inhibitor, which potentially induces cytotoxicity in CD74-expressing tumor cells (Blood (2024) 144 (Supplement 1): 604). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06563804 | Phase Ib/II | S227928 + Venetoclax S227928 | A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML | Recruiting | USA | FRA | FIN | DEU | AUS | 1 |